| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1053244835 |
| P356 | DOI | 10.1186/S12936-015-0991-X |
| P932 | PMC publication ID | 4661991 |
| P698 | PubMed publication ID | 26610844 |
| P5875 | ResearchGate publication ID | 284771171 |
| P2093 | author name string | Jun Liu | |
| William F McCarthy | |||
| Bryan Smith | |||
| Geoffrey S Dow | |||
| Gina Lin | |||
| Douglas Tang | |||
| Brian Hetzell | |||
| Sarah Thieling | |||
| P2860 | cites work | A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area. | Q37617688 |
| Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team | Q41920606 | ||
| Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. | Q41937668 | ||
| Long-term malaria prophylaxis with weekly mefloquine | Q41937874 | ||
| A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum | Q44320940 | ||
| Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis | Q44702083 | ||
| Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria | Q45056153 | ||
| A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers. | Q45918491 | ||
| Detecting and describing heterogeneity in meta-analysis | Q74573466 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Statistical aspects of the analysis of data from retrospective studies of disease | Q27860916 | ||
| A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria | Q28204425 | ||
| The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific | Q28283243 | ||
| Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects | Q33613720 | ||
| Modest additive effects of integrated vector control measures on malaria prevalence and transmission in western Kenya | Q37042548 | ||
| Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki | Q37052790 | ||
| The use of non-prescribed anti-malarial drugs for the treatment of malaria in the Bolgatanga municipality, northern Ghana | Q37075278 | ||
| P921 | main subject | placebo | Q269829 |
| malaria | Q12156 | ||
| P304 | page(s) | 473 | |
| P577 | publication date | 2015-11-26 | |
| P1433 | published in | Malaria Journal | Q15749954 |
| P1476 | title | Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries | |
| P478 | volume | 14 |
| Q64056980 | Clinical utility of tafenoquine in the prevention of relapse of malaria: a review on the mode of action and emerging trial data |
| Q37480757 | Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei |
| Q90310182 | Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review |
| Q58089503 | Tafenoquine for travelers' malaria: evidence, rationale and recommendations |
| Q38774112 | The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg). |
Search more.